A recent systematic review and meta-analysis highlights the evolving global burden of Mpox in the paediatric population. Since clinicians in India must remain vigilant after recent Clade 1b reports, understanding Pediatric Mpox Clinical Manifestations is vital. This research synthesized data from 22 primary studies published between 2023 and 2024. Consequently, it provides a comprehensive overview of how this viral disease affects children across diverse geographic settings.

Pediatric Mpox Clinical Manifestations and Risk Factors

The meta-analysis revealed significant variability in PCR positivity rates. Specifically, non-endemic regions reported rates of 6.95%, while endemic areas saw 35.6%. Furthermore, the primary Pediatric Mpox Clinical Manifestations include progressive skin lesions and fever. Younger children are more susceptible to severe complications. However, household contact remains the most frequent risk factor for this age group. Additionally, socioeconomic factors and coinfections play a significant role in increasing disease severity.

Moreover, the study emphasizes the need for age-specific public health interventions. Improved diagnostic capabilities in endemic regions could drastically reduce morbidity. Because socioeconomic factors often delay care, clinicians must prioritize early diagnosis through molecular testing. Standardised clinical guidelines are also essential to improve clinical outcomes for pediatric patients globally. Supportive care remains the cornerstone of treatment, though severe cases might require antivirals.

Standardizing Pediatric Care

Effective management requires a high index of suspicion when children present with a vesiculopustular rash. Although many cases are self-limiting, the potential for respiratory distress or secondary infections exists. Furthermore, addressing household transmission through parent education is a critical step in controlling local outbreaks. Continued surveillance is necessary to monitor evolving viral clades and their impact on the youngest populations.

Frequently Asked Questions

How do pediatric Mpox symptoms differ from those in adults?

While both groups experience fever and rash, children—especially those under eight—are at a higher risk for severe complications like encephalitis or secondary pneumonia. Pediatric cases often feature more rapid lesion progression than adult cases.

What are the primary modes of transmission for children?

In most pediatric cases, transmission occurs through close household contact with an infected caregiver. For adolescents, however, sexual transmission has become an increasingly significant route in recent outbreaks.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Dsouza VS et al. Epidemiology and clinical manifestation of mpox in children: Systematic review and meta-analysis. Glob Public Health. 2026 Dec 31. doi: 10.1080/17441692.2026.2648960. PMID: 41922934.


2. Singh T, Sharma S. Mpox in India: Current Insights and Strategic Recommendations. Indian J Community Med. 2025 May-Jun;50(3):539-543. doi: 10.4103/ijcm.ijcm_723_24.


3. Hennessee I, et al. Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(44):1407–1411.